Deutsch A, Frishman W H, Sukenik D, Somer B G, Youssri A
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461.
J Clin Pharmacol. 1994 Dec;34(12):1133-47. doi: 10.1002/j.1552-4604.1994.tb04723.x.
Atrial natriuretic peptide (ANP) is a 28 amino-acid polypeptide secreted into the blood by atrial myocytes after atrial pressure and distension. Although its role in humans is not clear, it can produce a variety of physiologic effects including vasodilatation, natriuresis, and suppression of the renin-angiotensin-aldosterone axis. These actions are potentially useful in a variety of pathologic states such as hypertension and congestive heart failure, and diverse methods to augment the effects of ANP in these states have been devised. The results are exciting and, despite some problems, may lead to the pharmacologic use of enhancement of ANP actions in several clinical disorders.
心房利钠肽(ANP)是一种由心房肌细胞在心房压力和扩张后分泌入血的含28个氨基酸的多肽。尽管其在人类中的作用尚不清楚,但它可产生多种生理效应,包括血管舒张、利钠以及抑制肾素-血管紧张素-醛固酮轴。这些作用在多种病理状态如高血压和充血性心力衰竭中可能有用,并且已经设计出多种方法来增强ANP在这些状态下的作用。结果令人振奋,尽管存在一些问题,但可能会导致在几种临床疾病中对增强ANP作用进行药物应用。